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A B S T R A C TObjectives: Estimation of the effectiveness of human papillomavirus
(HPV) vaccination in the open population on the basis of published
data from various sources. Methods: A Bayesian approach was used
to reanalyze the data underlying a guidance by the Dutch National
Health Insurance Board about the quadrivalent HPV vaccine Gardasil.
Several studies document the vaccine’s effectiveness in preventing
cases in different subpopulations. None of these (sub)populations,
however, is representative of the actual target population that the
vaccination program will be applied to. We used a Bayesian approach
for restructuring the data by means of reweighting the subpopulations
by using HPV prevalence data, to estimate the effectiveness that can
be expected in the actual target population. Results: The original data
show an effectiveness of 44% in the entire population and an
effectiveness of 98% for women who were compliant and were HPV-
free at the start of the study. In the study population, the HPV
prevalence was below 4%. In the relevant target population, however,see front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.01.001
man@ebh.umcn.nl.
ndence to: Willem Woertman, Department for Hea
he Netherlands.the actual prevalence could be very different. In fact, some publica-
tions find an HPV prevalence of around 10%. We used Bayesian
techniques to estimate the effectiveness in the actual target popula-
tion. We found a mean effectiveness of 25%, and the probability that
the effectiveness in the target population exceeds 50% is virtually
zero. The results are very sensitive to the HPV prevalence that is used.
Conclusions: A supplementary analysis can put together the bits and
pieces of information to arrive at more relevant answers. A Bayesian
approach allows for integrating all the evidence into one model in a
straightforward way and results in very intuitive probability
statements.
Keywords: Bayesian analysis, decision support techniques, evidence-
based medicine, Gardasil, health insurance reimbursement.
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Policy decisions concerning reimbursement of drugs have cru-
cially important implications for access to medical treatments for
patients. Therefore, the available evidence on clinical effective-
ness and cost-effectiveness of drugs should be carefully considered
and synthesized when reimbursement decisions are made.
This task is frequently hampered because the available evidence
is incomplete or inconsistent. Also, the evidence may originate
from multiple, heterogeneous sources, including randomized
controlled trials, cohort studies, record reviews, registries, labo-
ratory studies, and clinical and patients’ experiences. It is rarely
the case that there exists evidence that directly answers the
questions that are most relevant for decision makers. Instead,
there are usually bits and pieces of information available that
answer subquestions that are relevant to the policy decision
under consideration. Therefore, it often seems that there is a
mismatch between the questions that policymakers are grapp-
ling with and the answers that science typically offers. Here, we
argue that a supplementary analysis that combines all therelevant pieces of information (in the sense of a multiparameter
evidence synthesis [1] or as in the confidence profile method [2])
might come closer to actually answering the main questions that
decision makers are dealing with, and could therefore be very
helpful in the policymaking process. Furthermore, we argue that
Bayesian methods are well suited for such a supplementary
analysis. Most of the literature on multiparameter evidence
synthesis or the confidence profile method works within a
Bayesian framework [1]. Moreover, it has often been suggested
that a Bayesian approach to data analysis may be better suited
than the standard frequentist methods for answering policy
questions (e.g., [3–11]). There are two main reasons for this. First,
a Bayesian approach offers a natural way for combining evidence
from different sources in a systematic and transparent way, even
when dealing with heterogeneous sources of evidence. In
Bayesian statistics, unlike in frequentist statistics, it is very
common to consider the new information that is gathered from
an experiment together with the information that was available
before the experiment. The Bayesian approach offers a formalSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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information, so that previously held judgments are updated.
Second, Bayesian statistics has important conceptual advantages
over frequentist statistics, making the outcomes easier to interpret
and understand for relative laypersons (i.e., members of appraisal
committees). For instance, the frequentist concept of the P-value
gives an estimate of the probability of obtaining an outcome equal
to or more extreme than the observed outcome, under the null
hypothesis of no effect. This P-value, however, does not provide a
direct statement about how unlikely the null hypothesis in fact is,
nor how likely any alternative hypothesis. Arguably, however, this is
precisely the sort of statement that the various stakeholders would
like to be able to make: what is the probability that intervention x
will produce an effect of y (or larger), given the observed results z?
Bayesian analyses do produce such probabilities. Therefore, when
used as a supplement to the standard frequentist results, perhaps
Bayesian statistics could aid policymakers in comprehending and
assessing what the data have to say about the questions that are
most relevant to the problems they face.
In spite of these potential advantages, the Bayesian approach
is relatively unfamiliar and relatively little used in the context of
supporting policy decisions.
To put the alleged advantages of Bayesian methods for policy-
making to the test, we performed a Bayesian reanalysis of an
actual reimbursement advice that was drafted in 2009 by the
National Health Insurance Board of The Netherlands (College
voor Zorgverzekeringen [CVZ]), and compared the outcomes with
the original results.
The Case of Gardasil
Gardasil is a prophylactic quadrivalent vaccine that prevents
anogenital diseases associated with human papillomavirus (HPV)
types 6, 11, 16, and 18. Infection with HPV is sexually transferable
and can cause genital warts, intraepithelial neoplasia, and inva-
sive cancers [12]. Of these diseases, cervical cancer is particularly
important as it is the second most common cancer in women [13].
HPVs cause virtually all cervical cancers, and HPV types 16 and 18
cause approximately 70% of all HPV-related cervical cancers
worldwide [13]. HPV types 6 and 11 cause most genital warts [12].
In 2007 and 2008, CVZ issued two advises to the Dutch Minister
of Health about the reimbursement of Gardasil [14,15]. In 2007, CVZ
recommended that Gardasil should not be reimbursed for 13- to
26-year-old women and girls [14]. CVZ acknowledged the thera-
peutic added value of Gardasil, but was not convinced of its
cost-effectiveness. Shortly thereafter, the Dutch Health Council
recommended including HPV vaccination in the national vaccina-
tion program for 12-year-old girls and that girls who were then 13
to 16 years old would also be eligible for vaccination [16]. After that,
in 2008, the manufacturer of Gardasil asked for a reassessment,
with the request to reimburse the vaccine for 17- and 18-year-old
girls as well. For the same reasons as in 2007, CVZ advised not to
reimburse Gardasil [15]. In both advices, one of CVZ’s main points
of critique regarding the cost-effectiveness model supplied by the
manufacturer was the effectiveness of the vaccine that was used in
the model. In the first advice, the cost-effectiveness model used
the per-protocol susceptible effectiveness from one of the phase
3 trials. CVZ considered this assumption to be unrealistic and
overly optimistic. In the second advice, in the new cost-effective-
ness model supplied by the manufacturer, attempts were made to
correct for existing HPV-16/18 prevalence, but CVZ maintained that
the assumptions were not sufficiently supported by data.
In both advices, the evidence came from a variety of sources,
and was analyzed with standard frequentist methods. The main
articles that the advices refer to were a small phase 2 trial [17] and
two large placebo controlled phase 3 trials (FUTURE I AND II [12,13]).
The largest of these studies, the FUTURE II study, uses (thesurrogate outcome measure of) HPV-16/18–related cervical intra-
epithelial neoplasia grade 2 or 3, adenocarcinoma in situ, or cervical
cancer as the primary end point [13]. In the FUTURE II study, both
the placebo arm and the vaccine arm participants received injec-
tions at day 1, month 3, and month 6 of the follow-up period. The
main measure of effectiveness that was used is the proportion of
events that are prevented through vaccination, given by one minus
the vaccine event rate divided by the placebo event rate. The
FUTURE II study contained three main analyses, corresponding to
three different populations: 1) the per-protocol susceptible popula-
tion of women and girls, who were uninfected with HPV-16/18 until
1 month after the third and final injection, who received all the
injections at approximately the right moment, and who had no
other protocol violations; 2) an unrestricted susceptible population
of women who were uninfected with HPV-16/18 at the day of the
first injection; and 3) an intention-to-treat population of all partic-
ipating women in the study. All participants who belong to the first
population also belong to the second population, and all partic-
ipants who belong to the second population also belong to the
third. Women were eligible to participate in these studies if they
were not pregnant, if they did not report abnormal results on a Pap
smear, and if they had a lifetime number of no more than four sex
partners. Moreover, subjects were asked to use effective contra-
ception during the vaccination period (day 1 through month 7).
Clearly, not all women and girls were eligible to participate in
these studies. Considering the exclusion criteria, it seems likely
that among the women who were excluded the HPV prevalence
would be higher than among the women who were included in
the study. Indeed, a higher number of lifetime sex partners is
strongly associated with HPV prevalence [18]. Also, it is known
that HPV vaccination has no therapeutic benefit for women who
are already infected with HPV before vaccination. In contrast, for
women who were uninfected at the time of vaccination, Gardasil
is highly effective in preventing events with effectiveness near
100% [13]. Therefore, the HPV-16/18 prevalence before vaccination
in the population that is to be vaccinated will be a major
determinant of the effectiveness that will eventually be found.
Because even in the intention-to-treat populations the HPV-16/18
prevalence prior to vaccination will probably be lower than the
HPV-16/18 prevalence in the open population, the intention-to-
treat effectiveness is also likely to be an overestimate of the
effectiveness in the actual target population.
Therefore, if we could estimate the effectiveness that can be
expected in the target population, based on the above-mentioned
effectiveness estimate and on information about the HPV prev-
alence, we would be much closer to a satisfactory answer to the
most relevant question: ‘‘What will be the effectiveness—and
therefore cost-effectiveness—among all girls who would in fact
be eligible for vaccination?’’Methods
Our supplementary analysis is mainly based on the data from the
FUTURE II study [13], which provides estimates for the vaccine’s
effectiveness in preventing cases in three different populations.
This article also reports the numbers of subjects and the number
of cases (having at least one primary end point event) underlying
the effectiveness estimates in each of these three populations.
We started our supplementary analysis by restructuring the
three populations that the FUTURE II study considers (popula-
tions 1, 2, and 3 from the previous section) into three other, newly
formed groups of participants, which we will denominate groups
A, B, and C. Group A exactly equals population 1 (the per-protocol
susceptible population) from the FUTURE II study. Group B
consists of subjects who were included in population 2 (the
unrestricted susceptible population), but who were not included
model{
1    mAv ~dbin(thetaAv,nAv)
2    mAp ~dbin(thetaAp,nAp)
3    mBv ~dbin(thetaBv,nBv)
4    mBp ~dbin(thetaBp,nBp)
5    mCv ~dbin(thetaCv,nCv)
6    mCp ~dbin(thetaCp,nCp)
7    inf ~dbin(prev,n)
8    thetaAv~dbeta(1,1)
9    thetaBv~dbeta(1,1)
10  thetaCv~dbeta(1,1)
11  thetaAp~dbeta(1,1)
12  thetaBp~dbeta(1,1)
13  thetaCp~dbeta(1,1)
14  prev~dbeta(1,1)
15  theta_v<-prev*thetaCv+
(1-prev)*comp*thetaAv+
(1-prev)*(1-comp)*thetaBv
16  theta_p<-prev*thetaCp+
(1-prev)*comp*thetaAp+
(1-prev)*(1-comp)*thetaBp
17  comp~dbeta(123.7,13.7)
18  effect<-100-100*theta_v/theta_p
19  p25<-step(effect-25)
20  p50<-step(effect-50)
}
list(mAv=1,nAv=5305,mBv=2,nBv=560,
mCv=80,nCv=222,mAp=42,nAp=5260,
mBp=20,nBp=603,mCp=86,nCp=217,
inf=47,n=482)
Fig. 1 – The WinBUGS code.
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uninfected with HPV-16/18 at the day of the first vaccination, but
who had protocol violations, who did not receive all three
injections (or not at the appropriate times), or who became
HPV-16/18 infected during the vaccination period. Thus, this
group consists of susceptible noncompliers. The last group of
participants that we distinguish, group C, consists of those who
were included in population 3 (the intention-to-treat population),
but who were not included in population 2. This group consists of
those who were eligible to enter the study but who were HPV-16/
18 infected on day 1 of follow-up. Thus, this group is an HPV-16/
18 prevalent group.
Then, from the numbers of subjects and cases in populations
1, 2, and 3 from the FUTURE II study, we can determine the
numbers of subjects and cases in groups A, B, and C. We denote
the number of subjects in population 1 who were randomized to
get the vaccine by n1
v and the number of cases in this group by m1
v,
the number of subjects in population 1 who got placebo injections
by n1
p, and the number of cases in this population by m1
p. And we
denote the corresponding numbers of subjects and cases in
populations 2 and 3, and in groups A, B, and C, by changing the
subscripts accordingly. Then, we get that nA
v ¼ n1v, that nBv ¼ n2v  n1v,
and that nC
v ¼ n3v – n2v. The same relations between groups A, B, C,
and populations 1, 2, and 3 hold for the cases mv in the vaccine
group, and the same goes for all the placebo numbers np and mp.
Thus, we were able to calculate the vaccine’s effectiveness in each
of our three groups of participants, which can be considered as
the HPV-16/18–naive per-protocol effectiveness, an HPV-16/
18–naive noncomplier effectiveness, and an HPV-16/18–infected
effectiveness. By reweighting these effectiveness measures, we
estimated the effectiveness in our target population.
Age-dependent data on the HPV prevalence in The Nether-
lands were obtained from the literature [19]. Although this study
does not provide data on exactly our target group, this study
probably provides the best available approximation of that
number (see the ‘‘Discussion’’ section).
For the proportion of noncompliers (those susceptible subjects
not getting all three injections or not at the appropriate times, or
those who get an HPV-16/18 infection during the vaccination
period), the only direct data we could find were from the FUTURE
studies, which showed noncompliance rates of around 10%.
Hence, we assumed a 95% interval for the noncompliance rate
from 5% to 15%.
Analyses were carried out by using Winbugs, a statistical
software package designed for Bayesian analysis. The WinBUGS
code for our Bayesian supplementary analysis is printed in
Figure 1.
We first estimated yA
v, the probability of a case in the vaccine
arm for group A, by using a binomial likelihood function, and the
number of subjects and cases found in that group (line 1 of the
WinBUGS code), and a noninformative (beta(1,1)) prior distribu-
tion (line 8). We similarly estimated yA
p, yB
v, yB
p, yC
v, and yC
p (lines 2–6
and 9–13). Thus, we arrived at a posterior distribution for each of
these six probabilities of a random subject being a case. We
similarly estimated the HPV prevalence by using a binomial
likelihood function, the number of HPV-16/18–infected women
and the sample size from Coupe et al. [19], and a noninformative
prior (lines 7 and 14). The three posterior distributions for the
vaccine arm yA
v, yB
v, and yC
v were combined into a posterior
distribution for the probability of being a case for the entire
vaccine arm yv by reweighting them by using the estimated HPV
prevalence and the proportion of compliers [line 15]. The above
95% interval for the proportion of compliers was expressed by
means of a beta distribution (line 17). We did the same for the
placebo arm of the study, also arriving at a posterior distribution
for the probability of being a case in the entire arm yp (line 16).
Having thus calculated the posterior distributions for theprobabilities of being a case in both the vaccine arm and the
placebo arm in our target population, we could determine a
posterior distribution for the vaccine’s estimated effectiveness
for preventing cases in our target population (line 18). It is
important to note that the alternative (and perhaps seemingly
more straightforward and simple) strategy of first calculating the
effectiveness in each of our three groups, and then simply
determining a weighted average of these three effectiveness
measures, is in fact incorrect.
The information contained in the posterior distribution for the
effectiveness in the target population was summarized by provid-
ing a mean and a Bayesian (equal-tail) 95% credible interval. We
also calculated the probabilities that the effectiveness in the target
population exceeds 50% or 25% (lines 19 and 20).
As the vaccine’s effectiveness for both groups of HPV-naive
participants (groups A and B) is high and the effectiveness in the
group of HPV-infected participants (group C) is dramatically lower,
the HPV prevalence is a crucial piece of information in our
combined analysis. Because we could not find prevalence informa-
tion for exactly the right group of women, we performed a
sensitivity analysis investigating the impact of the HPV prevalence
on the posterior distribution. Thus, we repeated our supplementary
analysis making four other assumptions regarding the HPV-16/18
prevalence: we replaced lines 7 and 14 of the WinBUGS code by a
line similar to line 17, thereby simply assuming 95% confidence
intervals (CIs) of (1, 3), (5, 10), (5, 15), and (10, 15). For each of these
CIs, we have tried to choose the parameters of the corresponding
beta distributions in such a way that the mean of the distribution
would be halfway between the lower bound and the upper bound,
so that the precise upper and lower bounds would be as close as
possible to the above rounded values.
For the Markov Chain Monte Carlo procedures that WinBUGS
performs for the Bayesian analyses, we took 50,000 iterations with
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 6 0 4 – 6 0 9 60720,000 for burn-in. We checked that the Markov Chain Monte Carlo
procedures had reached convergence by visually inspecting the
history trace plots and the cumulative quantile plots for irregu-
larities, and by checking that autocorrelation between lagged
iterations was not present. Thinning was applied only if there
were problems with autocorreleation.Results
The Original, Frequentist Results
The original data regarding the number of cases and the number
of subjects in both arms and each of the three populations from
the FUTURE II study [13] are displayed in Table 1. This table also
displays the vaccine’s estimated effectiveness in preventing cases
in the three populations, accompanied by (frequentist) 95% CIs.
In the per-protocol susceptible population, the effectiveness is
almost 100%, and only slightly less in the unrestricted susceptible
population. The estimated effectiveness in the intention-to-treat
population is much lower at 44%.
Table 1 also displays the number of cases and the number of
subjects in both arms for each of the three groups that we
reconstructed from the FUTURE II populations. Again, this table
also displays the vaccine’s estimated effectiveness in the three
groups and 95% CIs. In group B (the HPV-16/18–naive noncom-
pliers), the effectiveness is still high, but the estimated effective-
ness in group C (the HPV-16/18–prevalent group) is very low at 9%.
Coupe et al. [19] present HPV prevalence data for 18- to 24-
year-old Dutch women. They report 47 HPV-16/18 infections in a
sample of 482 women. This yields an estimate for the prevalence
of 9.8%, and a 95% CI of (7.1, 12.4). Note that this is substantially
higher than the HPV prevalence among women who are included
in the FUTURE II study. (The ratio of women in group C with the
total number of included women is about 3.6%.)
Results of the Bayesian Analysis
The Bayesian supplementary analysis resulted in a posterior
distribution for the vaccine’s effectiveness in the projected target
population. Summary data are displayed in Table 2. We found a
mean estimated effectiveness of 25% and a 95% credible interval
ranging from 7% to 41%. The probability that the true effective-
ness exceeds 25% is found to be 53%, and the probability that
the effectiveness in the target population exceeds 50% is
virtually zero.
Figure 2 shows the posterior probability distribution for the
effectiveness as well as a cumulative distribution plot for the
posterior distribution.Table 1 – The original FUTURE II data and the reorganiz
Population Vaccine arm
No. of cases No. of sub
Original data PPS 1 5305
US 3 5865
ITT 83 6087
Reorganized data A 1 5305
B 2 560
C 80 222
Note. Number of cases, number of subjects, and effectiveness for the
intention-to-treat (ITT) populations, as taken from the FUTURE II study
derived groups of participants (reorganized data).The sensitivity analysis shows that the HPV prevalence that is
used does strongly influence the posterior distribution (Table 2).
The base-case analysis assumed that the HPV-16/18 prevalence
was between 7% and 13%, with a mean of nearly 10%. When
using prevalence between 1% and 3%, a mean effectiveness of
63% resulted. If the prevalence ranges between 10% and 15%, the
expected effectiveness will be 22%.
In none of the above analyses, the convergence checks
showed any problems, and there was no need for thinning.Discussion
This article tries to illustrate that supplementary analyses, put-
ting together the bits and pieces of (partially) relevant informa-
tion, can help policymakers to better assess what the data have
to say about the problems they are dealing with. In this article,
we have performed such a supplementary analysis by using a
Bayesian approach. By doing this analysis, we were indeed able to
provide an answer to the question ‘‘What will be the effectiveness
in our target population?’’ that is much more relevant than the
answers to questions such as ‘‘What is the effectiveness in a per-
protocol population?’’ and ‘‘What is the effectiveness in a con-
strained intention-to-treat population?’’ Moreover, our Bayesian
outcomes allow for making statements such as ‘‘The probability
that the effectiveness in our target population will exceed 50% is
virtually zero,’’ which is arguably more relevant and easier to
interpret than the frequentist statement ‘‘The probability of
observing an effectiveness as large or larger than observed, if
the real effectiveness equals zero, is virtually zero.’’
Using Bayesian methods it is straightforward to link together
different subanalyses into one comprehensive analysis as we have
done here. Most of this could also have been approximated by using
non-Bayesian methods, for instance, by using formulas to deter-
mine the mean and variance of the resulting effectiveness variable
from the means and variances of the constituent parts (the six per
group measures for the probability of a case, the HPV prevalence,
and the proportion of compliers). This would, however, involve
normal approximations, and these approximations might not be
very good because some of the constituent parts are much skewed.
Underlying our analysis are a few assumptions that merit
discussion. First, to arrive at an estimate for the effectiveness in
the target population, we need information about the HPV
prevalence in this target population, and this seems to be a very
important bit of information. While Coupe et al. [19] provide
recent evidence from the population of Dutch women that we
were indeed interested in, this evidence did not originate from
exactly the right age group (we used estimates for 18–24-year-olded data.
Placebo arm Effectiveness
jects No. of cases No. of subjects (95% CI)
42 5260 98 (86–100)
62 5863 95 (85–99)
148 6080 44 (26–58)
42 5260 98 (87–99)
20 603 89 (58–97)
86 217 9 (0–28)
per-protocol susceptible (PPS), unrestricted susceptible (US), and
[13] (original data). The same quantities are shown for our newly
Table 2 – Bayesian results.
Analysis Prevalence 95% CI Mean 95% credible interval P(eff)4 0.5 (%) P(eff)4 0.25 (%)
Main analysis 7–13 25 7–41 0.0 53
SA1 1–3 63 30–91 76 99
SA2 5–10 30 12–46 0.5 73
SA3 5–15 27 7–44 0.0 58
SA4 10–15 22 3–38 0.0 38
Notes. Results from our main analysis (assuming a 95% interval for the HPV-16/18 prevalence ranging from 7% to 13%) and from four sensitivity
analyses (making alternative prevalence assumptions). Shown are summary data for the posterior distributions on the final effectiveness: the
mean, (Bayesian) 95% credible interval, and the probabilities that the effectiveness will exceed 50% and 25%.
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Lenselink et al. [18] also provide recent Dutch HPV prevalence
data, which does not exactly match the information we are
looking for either. Their data, however, seems to suggest that
the HPV-16/18 prevalence for 18-year-old girls would lie some-
where around 2% (a figure that is rather different from that found
by Coupe et al. [19]) and the first sensitivity analysis roughly
corresponds to these figures. We do choose to use the data from
Coupe et al. [19] in our base-case analysis for a number of
reasons. First, these data were available at the time the CVZ
advice was drafted (because we are doing a reanalysis). And
second, the estimates from Coupe et al. more or less seem to be
corroborated by Jacobs et al. [20] (although their sample is very
small) and Bogaards et al. [21,22]. Because the data on the HPV
prevalence are not unequivocal, however, we performed0 10 20 30 40 50
effectiveness
(A) posterior distribution
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0
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Fig. 2 – Posterior distributions. The posterior probability
distribution for the effectiveness (the proportion of HPV-16/
18–related events that can be prevented because of
vaccination) in the target population is shown in panel (A).
A cumulative probability function for the posterior
distribution is shown in panel (B). The vertical lines show
that the probability that the effectiveness in the target
population is smaller than 25% and 50% (the cumulative
probability) is 0.47 and approximately 1, respectively.sensitivity analyses making other assumptions on the HPV
prevalence than used in our base case. This showed that out-
comes are quite sensitive to varying the HPV prevalence. There-
fore, acquiring new information about the appropriate age group
could make our estimates more reliable.
Second, once the vaccination program would be operational,
the HPV prevalence in the population would start to reduce over
time. Moreover, as the (prevaccine) prevalence decreases, the
efficacy of the vaccine across the population will increase. There-
fore, our effectiveness estimates do not apply to longer time
horizons after implementation of the vaccination program.
Third, the proportion of noncompliers was based on an
assumption, which was made by taking an interval of values
around the noncompliance rates from the FUTURE trials (which
were approximately 10%). We based our assumptions on the
FUTURE trials because data on noncompliance in the current
sense (not getting all three injections or not at the appropriate
times, or getting an HPV-16/18 infection during the vaccination
period) can most probably be observed only in a trial situation. It
is possible or even likely, however, that when a vaccination
program is in fact offered, the noncompliance rate would be
higher than that found in a controlled trial situation. Moreover,
we could wonder whether it is reasonable to assume equal
noncompliance rates for both the placebo and the vaccine arms
as we have done. We also investigated the sensitivity of outcomes
to alternate noncompliance rates, but the effectiveness measure
proved not to be very sensitive to the noncompliance rate
(certainly when compared with the HPV prevalence) (data not
shown).
Fourth, in our analysis we have not made a distinction
between HPV type 16 or HPV type 18 infections. In reality, the
two types may be associated with different risk profiles, and we
could want to take this into account by dividing up our group of
HPV-16/18–infected subjects and by using separate HPV-16 and
HPV-18 prevalences. In our case, however, the data from the
FUTURE II study did not allow for making these distinctions. In a
similar vein, if we had sufficient data we could in principle refine
our analysis by distinguishing more groups. For instance, the
second group from Table 2 was treated here as noncompliers, but
if we look at the criteria that were used to distinguish the first
two populations from the FUTURE II study (and thus the first two
of our reorganized groups from Table 1), not all these subjects are
in fact noncompliers, and even those who are noncompliers may
be so because of different reasons. The methodology for the
supplementary analysis that is used in this article could certainly
be extended to allow for refinements of the cases and groups of
patients, provided that such data are available from the literature
or other sources.
We already noted that, based on numbers such as the per-
protocol effectiveness of 98% and the intention-to-treat effective-
ness of 44% from the FUTURE II study, CVZ concluded that the
effectiveness of Gardasil was sufficient. On the basis of our
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 6 0 4 – 6 0 9 609supplementary analysis, we can see that an effectiveness of 25%
is more likely in the actual target population and that
the probability that the vaccine’s effectiveness in the target
population exceeds 50% is virtually zero. Conceivably, having
the outcomes from our supplementary analysis would have
changed CVZ’s opinion about the prophylactic effectiveness of
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